These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 22027143)

  • 1. Tetranor PGDM analyses for the amyotrophic lateral sclerosis: positive and simple diagnosis and evaluation of drug effect.
    Shinozawa T; Urade Y; Maruyama T; Watabe D
    Biochem Biophys Res Commun; 2011 Dec; 415(4):539-44. PubMed ID: 22027143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous and high-throughput quantitation of urinary tetranor PGDM and tetranor PGEM by online SPE-LC-MS/MS as inflammatory biomarkers.
    Zhang Y; Zhang G; Clarke PA; Huang JT; Takahashi E; Muirhead D; Steenwyk RC; Lin Z
    J Mass Spectrom; 2011 Jul; 46(7):705-11. PubMed ID: 21706677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein biomarkers for amyotrophic lateral sclerosis.
    Ryberg H; Bowser R
    Expert Rev Proteomics; 2008 Apr; 5(2):249-62. PubMed ID: 18466055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tetranor PGDM, an abundant urinary metabolite reflects biosynthesis of prostaglandin D2 in mice and humans.
    Song WL; Wang M; Ricciotti E; Fries S; Yu Y; Grosser T; Reilly M; Lawson JA; FitzGerald GA
    J Biol Chem; 2008 Jan; 283(2):1179-88. PubMed ID: 17993463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical features that distinguish PLS, upper motor neuron-dominant ALS, and typical ALS.
    Gordon PH; Cheng B; Katz IB; Mitsumoto H; Rowland LP
    Neurology; 2009 Jun; 72(22):1948-52. PubMed ID: 19487653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 10-metre gait speed as a functional biomarker in amyotrophic lateral sclerosis.
    Inam S; Vucic S; Brodaty NE; Zoing MC; Kiernan MC
    Amyotroph Lateral Scler; 2010 Dec; 11(6):558-61. PubMed ID: 20515425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can selection of rapidly progressing patients shorten clinical trials in amyotrophic lateral sclerosis?
    de Carvalho M; Swash M
    Arch Neurol; 2006 Apr; 63(4):557-60. PubMed ID: 16606769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Differential diagnosis and atypical subsets of amyotrophic lateral sclerosis].
    Pradat PF; Bruneteau G
    Rev Neurol (Paris); 2006 Jun; 162 Spec No 2():4S81-4S90. PubMed ID: 17128093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized sequential trial of creatine in amyotrophic lateral sclerosis.
    Groeneveld GJ; Veldink JH; van der Tweel I; Kalmijn S; Beijer C; de Visser M; Wokke JH; Franssen H; van den Berg LH
    Ann Neurol; 2003 Apr; 53(4):437-45. PubMed ID: 12666111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CSF glial markers correlate with survival in amyotrophic lateral sclerosis.
    Süssmuth SD; Sperfeld AD; Hinz A; Brettschneider J; Endruhn S; Ludolph AC; Tumani H
    Neurology; 2010 Mar; 74(12):982-7. PubMed ID: 20308682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Objective markers for upper motor neuron involvement in amyotrophic lateral sclerosis].
    Iwata NK
    Brain Nerve; 2007 Oct; 59(10):1053-64. PubMed ID: 17969345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiation between primary lateral sclerosis and amyotrophic lateral sclerosis: examination of symptoms and signs at disease onset and during follow-up.
    Tartaglia MC; Rowe A; Findlater K; Orange JB; Grace G; Strong MJ
    Arch Neurol; 2007 Feb; 64(2):232-6. PubMed ID: 17296839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amyotrophic lateral sclerosis.
    Jackson CE; Bryan WW
    Semin Neurol; 1998; 18(1):27-39. PubMed ID: 9562665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteome analysis reveals candidate markers of disease progression in amyotrophic lateral sclerosis (ALS).
    Brettschneider J; Lehmensiek V; Mogel H; Pfeifle M; Dorst J; Hendrich C; Ludolph AC; Tumani H
    Neurosci Lett; 2010 Jan; 468(1):23-7. PubMed ID: 19853641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No effect of creatine on respiratory distress in amyotrophic lateral sclerosis.
    Drory VE; Gross D
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2002 Mar; 3(1):43-6. PubMed ID: 12061948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteome analysis of body fluids for amyotrophic lateral sclerosis biomarker discovery.
    Krüger T; Lautenschläger J; Grosskreutz J; Rhode H
    Proteomics Clin Appl; 2013 Jan; 7(1-2):123-35. PubMed ID: 23129563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II Study Group.
    Arch Neurol; 1996 Feb; 53(2):141-7. PubMed ID: 8639063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amyotrophic lateral sclerosis.
    Gordon PH; Mitsumoto H; Hays AP
    Sci Aging Knowledge Environ; 2003 Sep; 2003(35):dn2. PubMed ID: 12954882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical characteristics of amyotrophic lateral sclerosis subsets].
    Pradat PF; Bruneteau G
    Rev Neurol (Paris); 2006 Jun; 162 Spec No 2():4S29-4S33. PubMed ID: 17128087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.